REMAP-CAP
A Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia
24,586
Patient randomisations
18,582
Patient randomisations with suspected or proven COVID-19
14,211
Total patients
10,421
Patients with suspected or proven COVID-19
66
Current or completed interventions in 18 Domains
298
Active Sites
A global health challenge
Community-acquired pneumonia (or CAP) is a significant cause of hospitalisation and illness world-wide. Respiratory tract infections are the leading cause of deaths from infectious disease globally, and are the leading cause of deaths in developing nations.
An innovative approach to critical care research
REMAP-CAP uses a novel and innovative adaptive trial design to evaluate a number of treatment options simultaneously and efficiently. This design is able to adapt in the event of pandemics, and increases the likelihood that patients will receive the treatment that is most likely to be effective for them.
An international collaboration
REMAP-CAP is a global network of leading experts, institutions and research networks. With over 250 participating world-wide, REMAP-CAP is a truly global trial.
Pandemics are impossible to predict, and may spread rapidly throughout the world. The REMAP-CAP trial provides a global research platform that is able to adapt to efficiently evaluate multiple treatment options for patients who are critically ill due to a global respiratory pandemic.
